Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.
Location: United States, California, Carlsbad
Employees: 11-50
Total raised: $15.4M
Founded date: 2017
Founders name: Paulo Rangel
Founders Related Locations: Haiti, Centre, Hinche; United States, California, Carlsbad; United States, California, San Diego
Investors 3
| Date | Name | Website |
| - | BioRock Ve... | biorockven... |
| - | Biobrit | biobrit.co... |
| - | Bioqube Ve... | bioqubeven... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.11.2021 | Series A | $8.4M | - |
| 08.03.2020 | Seed | $7M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Paulo | Rangel | Chief Busi... | linkedin.c... | - | - |
Mentions in press and media 11
| Date | Title | Description |
| 07.09.2024 | Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever | – PRTX007 program to support DTRA’s efforts to establish biological defense solution against Lassa fever and other hemorrhagic viruses – SAN DIEGO, March 20, 2024 – Primmune Therapeutics, a biotech company harnessing the power of the innate... |
| 22.04.2023 | Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting | — PRTX007 was shown to be well-tolerated with a favorable safety profile for all analyzed cohorts in the Phase 1 study — |
| 04.11.2021 | Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing | Primmune Therapeutics today announced that it has received $8.4 million in a second tranche of the Company’s Series A financing. The total proceeds for the equity raised in the Series A was $31.4 million. These funds will be used to support... |
| 12.01.2021 | Primmune Therapeutics has announced raising an additional $4M, bringing the total of the Series A round to $31.4M | - |
| 27.10.2020 | Primmune Therapeutics has announced a $27.4M Series A to advance the development of their novel treatment candidate for viral diseases and cancer | - |
| 08.03.2020 | Primmune Therapeutics has raised a $7M seed round to use the body's innate immune system against cancer | - |
| 02.03.2020 | Primmune Therapeutics Raises $7M in Seed Financing | Primmune Therapeutics, a San Diego, CA-based company that develops small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases, raised $7m in seed financing. Inv... |
| 02.03.2020 | Primmune Therapeutics Inks $7M Seed Financing | SAN DIEGO, CA, Primmune Therapeutics today announced that it has raised $7 million in seed financing. >> Click here for more funding data on Primmune Therapeutics >> To export Primmune Therapeutics funding data to PDF and Ex... |
| - | Primmune Therapeutics Strengthens Leadership Team with Key Appointments | SAN DIEGO, February 5, 2021 – Today, Primmune Therapeutics announced the appointment of Rich Daniels as Chief Operating Officer, Scott Zook as Senior Vice President, Global Manufacturing and Randy Adams as Senior Advisor, Commercial Develop... |
| - | Primmune Therapeutics Announces Close of Series A Financing | SAN DIEGO, January 12, 2021 – Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of ... |
Show more